RA Capital Management’s Solid Biosciences SLDB Stock Holding History

RA Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$67.2M	Buy	9,339,978 +3,528,555	+61%	+$22.7M	0.71%	29
2025 Q4	$32.8M	Hold	5,811,423	–	–	0.34%	44
2025 Q3	$35.9M	Buy	5,811,423 +100	+0%	+$585	0.44%	34
2025 Q2	$28.3M	Buy	5,811,323 +1,480,877	+34%	+$5.24M	0.48%	32
2025 Q1	$16M	Hold	4,330,446	–	–	0.27%	51
2024 Q4	$17.3M	Hold	4,330,446	–	–	0.23%	62
2024 Q3	$30.2M	Hold	4,330,446	–	–	0.35%	48
2024 Q2	$24.6M	Hold	4,330,446	–	–	0.32%	47
2024 Q1	$57.7M	Buy	4,330,446 +904,160	+26%	+$8.46M	0.73%	38
2023 Q4	$21M	Hold	3,426,286	–	–	0.33%	48
2023 Q3	$8.63M	Hold	3,426,286	–	–	0.17%	57
2023 Q2	$18M	Hold	3,426,286	–	–	0.34%	46
2023 Q1	$16.2M	Hold	3,426,286	–	–	0.37%	49
2022 Q4	$18.4M	Buy	3,426,286 +2,601,761	+316%	+$17.1M	0.37%	46
2022 Q3	$5.77M	Hold	824,525	–	–	0.12%	67
2022 Q2	$7.61M	Hold	824,525	–	–	0.2%	63
2022 Q1	$14.8M	Hold	824,525	–	–	0.32%	63
2021 Q4	$21.6M	Hold	824,525	–	–	0.38%	59
2021 Q3	$29.6M	Hold	824,525	–	–	0.41%	52
2021 Q2	$45.3M	Hold	824,525	–	–	0.73%	46
2021 Q1	$68.4M	Buy	824,525 +159,420	+24%	+$17.6M	1.03%	32
2020 Q4	$75.6M	Buy	665,105 +360,361	+118%	+$22.8M	1.06%	29
2020 Q3	$9.28M	Hold	304,744	–	–	0.17%	60
2020 Q2	$13.4M	Hold	304,744	–	–	0.26%	47
2020 Q1	$10.9M	Hold	304,744	–	–	0.35%	39
2019 Q4	$20.3M	Hold	304,744	–	–	0.62%	26
2019 Q3	$47.3M	Buy	304,744 +125,448	+70%	+$14.2M	2.82%	10
2019 Q2	$21.3M	Hold	179,296	–	–	1.14%	20
2019 Q1	$24.7M	Hold	179,296	–	–	1.07%	25
2018 Q4	$72.1M	Hold	179,296	–	–	4.2%	8
2018 Q3	$127M	Hold	179,296	–	–	6.78%	3
2018 Q2	$95.8M	Hold	179,296	–	–	6.22%	3
2018 Q1	$20.2M	Buy	+179,296	New	+$60.5M	1.55%	15

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RA Capital Management's SLDB Position: Q1 2026 in Review

RA Capital Management increased its Solid Biosciences (SLDB) stake by 61% in Q1 2026, buying an estimated $22.7M and bringing the position to 9,339,978 shares worth $67.2M. The position accounts for 0.71% of the portfolio, ranked #29.

RA Capital Management first reported a position in SLDB in Q1 2018 and has held it in 33 quarters since. The position peaked at $127M in Q3 2018. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

RA Capital Management held 9,339,978 shares of Solid Biosciences worth $67.2M as of Q1 2026.
RA Capital Management bought 3,528,555 Solid Biosciences shares in Q1 2026, an estimated $22.7M.
Solid Biosciences made up 0.71% of RA Capital Management's portfolio in Q1 2026, its #29 holding.
RA Capital Management first reported a position in Solid Biosciences in Q1 2018 and has held it in 33 quarters since.
RA Capital Management's Solid Biosciences position peaked at $127M in Q3 2018.
150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.